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Failure of Ceftriaxone in an Intravenous 
Drug User with Invasive Infection 
Due to Ralstonia pickettii
C. Zellweger, T. Bodmer, M. G. Täuber, K. Mühlemann
Abstract
We report a case of septic arthritis due to Ralstonia pickettii
in an intravenous drug user with unfavorable clinical course
under antibiotic therapy with ceftriaxone despite in vitro
susceptibility to the drug. The treatment failure may have
been due to a discrepancy between in vitro and in vivo
susceptibility of R. pickettii, or to resistance development
mediated by a recently described inducible ß-lactamase. 
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Introduction
Ralstonia pickettii, formerly known as Pseudomonas
(Burkholderia) pickettii, is a nonfermenting gram-nega-
tive rod. On the basis of DNA-DNA and DNA-rRNA ho-
mology studies, the germ belongs to the Pseudomonas ho-
mology group II. R. pickettii is a ubiquitous environmen-
tal organism, which can be found in water, soil, and plants
including fruits and vegetables. Nosocomial outbreaks due
to contamination of intravenous solutions,“sterile” water,
saline, chlorhexidine solutions, respiratory therapy solu-
tions, and intravenous catheters with R. pickettii have been
described [1].This microorganism has also been associated
with asymptomatic colonization of the respiratory tract as,
for example, in cystic fibrosis patients [1]. Due to bio-
chemical similarities, R. pickettii may be confounded with
Burkholderia cepacia, which can cause exacerbations of
pulmonary disease in patients with cystic fibrosis [2]. In
humans, R. pickettii is an infrequent cause of invasive in-
fections such as bacteremia [3, 4], meningitis [5], endo-
carditis [6] and osteomyelitis [7]. Here, we describe a pa-
tient with intravenous drug use, who developed severe in-
vasive infection due to R. pickettii. Of note, we found a dis-
crepancy between in vitro susceptibility to ceftriaxone and
clinical response to therapy with this antibiotic. The rea-
son for this phenomenon is unclear and may be due either
to uncertainties about breakpoints, or to induction of re-
sistance during antibiotic therapy.
Case Report
In October 2000, a 24-year-old male intravenous drug user was ad-
mitted to hospital for suspected intoxication. A few hours after
admission he developed signs of severe septicemia and a stiff neck.
White blood cell count (11.9  109/l) and C-reactive protein (291
mg/l) were elevated. A CT scan of the head was normal. Cere-
brospinal fluid examination revealed pleocytosis of 106  106/l
with 86% polymorphonuclear cells, protein 0.74 g/l, glucose 
4.91 mmol/l; no microorganisms were seen on Gram staining and
cultures remained sterile. Empirical antibiotic therapy with cef-
triaxone, vancomycin, and amoxicillin for meningitis was initiated.
Blood cultures grew Group A streptococcus. A transesophageal
echocardiogram revealed a thickened anterior mitral valve with
prolapse and a partially flail leaflet with moderate valve insuffi-
ciency, consistent with endocarditis. On the 2nd day of hospital-
ization, redness and swelling was noted in the area of the right el-
bow and the left knee. Both joints were surgically drained.
Aspirates of both joints yielded a gram-negative rod, which
was identified as R. pickettii with the commercial gallery API 20NE
(bioMérieux Vitek, Hazelwood, MO).The identification was con-
firmed by cellular fatty acid analysis using the Microbial Identifi-
cation System (Microbial ID, Inc., Newark, DE). The antimicro-
bial susceptibility testing was performed according to the National
Committee for Clinical Laboratory Standards for disk suscepti-
bility testing. Susceptibility testing was done on Mueller-Hinton
agar. The plates were incubated aerobically at 35 °C without CO2
for 24 h. By disk diffusion the microorganism appeared sensitive
to piperacillin, piperacillin/tazobactam, higher generation
cephalosporins (including cefuroxime, ceftriaxone, ceftazidime, ce-
fepime), imipenem, trimethoprim-sulfamethoxazole, and
ciprofloxacin. Intermediate sensitivity was found for aztreonam
and netilmicin. In vitro resistance was noted for ampicillin/clavu-
lanate, ticarcillin/clavulanate, meropenem, gentamicin, to-
bramycin, and amikacin. Minimal inhibitory concentrations (MIC)
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determined by E-test (AB Biodisk, Solna, Sweden) were 0.750
mg/l for ceftriaxone and 0.047 mg/l for ciprofloxacin.
In accordance with culture results and antibiotic resistance
testing, the treatment regimen was changed to ceftriaxone 2 g qd
for the endocarditis caused by Group A streptococcus and the sep-
tic polyarthritis due to R. pickettii. However, the clinical response
to this therapy was unsatisfactory. Levels of C-reactive protein re-
mained elevated at 114 mg/l and, after 2 weeks, purulent arthritis
of the knee recurred, requiring repeated surgical drainage. Cul-
tures of joint aspirate remained sterile.The treatment regimen was
changed from ceftriaxone to oral ciprofloxacin 500 mg bid and
penicillin G 24 Mio E qd. Under this regimen, the clinical and lab-
oratory findings improved. Because of progressive heart failure,
the mitral valve was replaced.A eubacterial polymerase chain re-
action performed on the valve revealed DNA of Group A strep-
tococcus; R. pickettii DNA was not detected.
The further clinical course was complicated by pericardial tam-
ponade and partial thrombosis of the portal vein. The patient was
discharged to further rehabilitation 8 weeks after admission. Two
weeks later, however, he had to be transferred back to the hospital
because of sternal wound infection with two different strains of me-
thicillin-resistant Staphylococcus aureus. At that time, and at fol-
low-up examination 1 1/2 months later, arthritis of the right elbow
and the left knee had healed without sequelae.
Discussion
Polymicrobial invasive infections are not uncommon in in-
travenous drug users.This patient had a dual infection with
Group A streptococcus and R. pickettii. Group A streptoc-
cocus was isolated from blood cultures and indirectly (eu-
bacterial polymerase chain reaction) from the mitral valve,
while R. pickettii was isolated from two different joint as-
pirates (elbow and knee).These samples were not collected
in blood culture bottles, but inoculated on solid media.Also,
the isolation of the pathogen from two different sites makes
a contamination unlikely.
The involvement of two separate joints indicates that
the patient experienced at least transient bacteremia with
R. pickettii.Whether this pathogen also played a role in the
endocarditis is not certain, but appears unlikely, based on
the eubacterial polymerase chain reaction from the cardiac
vegetation, which only documented Group A streptococcal
genome. Along the same line, a contribution of the Group
A streptococcus to the septic arthritis, while not ruled out,
could not be documented microbiologically.
Based on published reports, R. pickettii rarely causes
severe invasive infection. Several nosocomial outbreaks
have been described in pediatric or oncology wards [8–10]
and intensive care units [11] due to contamination of flu-
ids. Most invasive infections seem to occur in patients with
underlying diseases such as cancer, chronic renal failure, or
they are related to foreign bodies (intravenous catheters).
Here, we describe for the first time an invasive infection in
an intravenous drug user.The source of infection was most
likely the tap water, which the patient used to rinse his hy-
podermic needles.
The septic arthritis due to R. pickettii involving two sep-
arate joints showed an unfavorable clinical course under
therapy with ceftriaxone, despite in vitro susceptibility of
the organism initially isolated. Given the well-documented
efficacy of ceftriaxone in the therapy of septic arthritis and
bone infections, it is unlikely that this failure was caused by
insufficient drug penetration into the infected joints. Rather
it raises the question whether the in vitro testing for this or-
ganism, for which there is a lack of defined breakpoints, is
predictive of the in vivo response.
It has been suggested that interpretative standards for
Pseudomonas aeruginosa may be used for R. pickettii [1].
Therefore, a MIC of 0.750 mg/l for ceftriaxone would indi-
cate susceptibility to this drug.The unfavorable clinical re-
sponse in this case is reminiscent of the well-described dis-
parity between in vitro MIC, and in vivo efficacy for -lac-
tam antibiotics with P. aeruginosa [12].
It is also conceivable that the organism developed re-
sistance to -lactam antibiotics during therapy with ceftri-
axone. Although the resistance mechanisms in R. pickettii
are not known in detail, intrinsic, acquired, and genetic re-
sistance patterns similar to those of other gram-negative
bacteria must be considered. Recently, Nordmann et al. [13]
described a naturally occurring chromosomal and inducible
Ambler class D ß-lactamase, oxacillinase 22 (OXA-22), in
a clinical isolate of R. pickettii. OXA-22-like genes were fur-
ther identified in five other clinical isolates. In susceptibil-
ity tests where MICs of selected -lactams were determined
R. pickettii isolates were resistant, or had decreased sus-
ceptibility, against amino- and ureidopenicillins, restricted-
spectrum cephalosporins, ceftazidime, and aztreonam, while
susceptibility to ceftriaxone was not studied. Though not
tested, it is reasonable to assume that ceftriaxone is also, at
least partially, hydrolysed by OXA-22. In addition, the ex-
pression of OXA-22 is inducible in R. pickettii [13]. Unfor-
tunately, development of resistance during therapy could
not be tested, since the organism could not be recovered in
the second joint aspirates.
In conclusion, R. pickettii, mainly known as an oppor-
tunistic pathogen of nosocomial infection, can cause severe
invasive infection. Here, we describe the first case of septic
polyarthritis due to R. pickettii in an intravenous drug user
with a polymicrobial infection.The choice of the appropri-
ate antibiotic regimen for infections due to R. pickettii, es-
pecially in the case of polymicrobial infections, may be dif-
ficult due to the lack of interpretative breakpoints for in
vitro susceptibility tests, and scarce knowledge about the
antibiotic resistance mechanisms used by this pathogen. In-
ducible -lactamase activity in R. pickettii (mediated by
oxacillinase OXA-22 or OXA-22-like -lactamase) has to
be considered. Fluoroquinolones may provide effective
therapy when in vitro testing indicates susceptibility to this
class of antibiotics.
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